Rosedale Therapeutics

Rosedale Therapeutics is a biopharmaceutical company focused on developing first-in-class treatments for heart failure, particularly heart failure with preserved ejection fraction (HFpEF). A spin-out from the University of Glasgow, the company leverages decades of research into protein-protein interactions (PPI) to target the phosphodiesterase 4 (PDE4) enzyme with high precision. Their lead program aims to restore calcium handling in cardiac cells by disrupting the specific interaction between PDE4D and the ryanodine receptor (RyR2). This approach seeks to provide a more targeted therapy compared to traditional PDE inhibitors, potentially reducing systemic side effects while significantly improving cardiac function. The company is currently advancing its lead small molecule candidates through pre-clinical studies to support future clinical development.